Lineage Cell Therapeutics, Inc. Marketable Securities, Unrealized Gain (Loss)
Lineage Cell Therapeutics, Inc. (LCTX) reported Marketable Securities, Unrealized Gain (Loss) of $50.00 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-10.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2023-08-10
- Lineage Cell Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2023-06-30 was $50.00K.
- Lineage Cell Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2023-03-31 was $91.00K.
- Lineage Cell Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2022-12-31 was $0.00.
- Lineage Cell Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2022-09-30 was -$150.00K.
- Lineage Cell Therapeutics, Inc. marketable securities, unrealized gain (loss) for fiscal 2022 was -$150.00K.
- Lineage Cell Therapeutics, Inc. marketable securities, unrealized gain (loss) for fiscal 2020 was -$3.78M.
- Lineage Cell Therapeutics, Inc. marketable securities, unrealized gain (loss) for fiscal 2019 was -$2.90M, a 350.26% decline from fiscal 2018.
- Lineage Cell Therapeutics, Inc. marketable securities, unrealized gain (loss) for fiscal 2018 was $1.16M.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2023-06-30 | $50.00K 10-Q · filed 2023-08-10 | $141.00K 10-Q · filed 2023-08-10 | $141.00K derived: sum of 3 quarters · filed 2023-08-10 | -$9.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | $91.00K 10-Q · filed 2023-05-11 | $91.00K derived: sum of 2 quarters · filed 2023-05-11 | -$59.00K derived: sum of 3 quarters · filed 2023-05-11 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$150.00K derived: sum of 2 quarters · filed 2023-03-09 | -$150.00K 10-K · filed 2023-03-09 | |
| 2022-09-30 | -$150.00K 10-Q · filed 2022-11-10 | -$150.00K 10-Q · filed 2022-11-10 | ||
| 2020-12-31 | $3.71M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $1.70M derived: sum of 2 quarters · filed 2021-03-11 | -$2.44M derived: sum of 3 quarters · filed 2021-03-11 | -$3.78M 10-K · filed 2021-03-11 |
| 2020-09-30 | -$2.00M 10-Q · filed 2020-11-04 | -$6.15M derived: sum of 2 quarters · filed 2020-11-04 | -$7.49M 10-Q · filed 2020-11-04 | -$7.25M derived: sum of 4 quarters · filed 2021-03-11 |
| 2020-06-30 | -$4.15M 10-Q · filed 2020-08-06 | -$5.48M 10-Q · filed 2020-08-06 | -$5.25M derived: sum of 3 quarters · filed 2021-03-11 | -$9.71M derived: sum of 4 quarters · filed 2021-03-11 |
| 2020-03-31 | -$1.34M 10-Q · filed 2020-05-07 | -$1.10M derived: sum of 2 quarters · filed 2021-03-11 | -$5.56M derived: sum of 3 quarters · filed 2021-03-11 | -$6.17M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-12-31 | $236.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$4.22M derived: sum of 2 quarters · filed 2021-03-11 | -$4.83M derived: sum of 3 quarters · filed 2021-03-11 | -$2.90M 10-K · filed 2021-03-11 |
| 2019-09-30 | -$4.46M 10-Q · filed 2020-11-04 | -$5.07M derived: sum of 2 quarters · filed 2020-11-04 | -$3.13M 10-Q · filed 2020-11-04 | -$2.61M derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | -$607.00K 10-Q · filed 2020-08-06 | $1.32M 10-Q · filed 2020-08-06 | $1.85M derived: sum of 3 quarters · filed 2020-08-06 | $1.87M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $1.93M 10-Q · filed 2020-05-07 | $2.45M derived: sum of 2 quarters · filed 2020-05-07 | $2.48M derived: sum of 3 quarters · filed 2020-05-07 | $2.87M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $523.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $546.00K derived: sum of 2 quarters · filed 2020-03-12 | $943.00K derived: sum of 3 quarters · filed 2020-03-12 | $1.16M 10-K · filed 2020-03-12 |
| 2018-09-30 | $23.00K 10-Q · filed 2019-11-12 | $420.00K derived: sum of 2 quarters · filed 2019-11-12 | $635.00K 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $397.00K 10-Q · filed 2019-08-08 | $612.00K 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $215.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |